A recent study published in Nature Mental Health has shed light on the brain’s potential for recovery in individuals with heroin addiction undergoing inpatient treatment. The research, which focused on the brain’s inhibitory control processes, found significant improvements in brain activity related to self-control following 15 weeks of inpatient treatment. These findings offer hope for more effective interventions in addressing heroin addiction.
The opioid epidemic continues to be a major public health crisis, with over 100,000 overdose-related deaths in the United States in 2021 alone. Heroin addiction, a significant contributor to this epidemic, presents unique challenges for treatment due to its severe impact on brain function, particularly in areas responsible for inhibitory control and decision-making. Inhibitory control refers to the brain’s ability to suppress impulsive behaviors, a critical function often impaired in drug addiction.
Previous research has highlighted the role of the prefrontal cortex, a brain region essential for self-control, in addiction. However, there has been limited longitudinal research on how inpatient treatment might restore brain function related to inhibitory control in heroin addiction. This study aimed to fill this gap by examining brain activity changes in individuals with heroin addiction over a 15-week inpatient treatment period.
“Our lab has been studying impairments in response inhibition and salience attribution (the iRISA model) and their underlying prefrontal cortex (and other mesocorticolimbic) substrates in human drug (primarily cocaine) addiction for several decades. In this study, we sought to extend our focus to heroin addiction, associated with still escalating morbidity and mortality, and to potential brain inhibitory control changes with inpatient treatment,” said study author Ahmet O. Ceceli, a postdoctoral fellow at the Neuropsychoimaging of Addiction and Related Conditions Research Program. t the Icahn School of Medicine at Mount Sinai.
The study involved two groups: 26 individuals with heroin addiction (referred to as the iHUD group) and 24 healthy control participants (the HC group), matched for age and sex. The iHUD participants were recruited from a medication-assisted inpatient rehabilitation facility, while the HC participants were recruited from the surrounding community. The researchers used a combination of clinical interviews, behavioral tasks, and functional magnetic resonance imaging (fMRI) to assess brain function.
The primary focus was on the stop-signal task, a well-established measure of inhibitory control. In this task, participants were required to press a button in response to a visual cue (a white arrow) but to stop their response if the arrow turned red. This task was administered during two fMRI sessions, one at the beginning of the study and one after 15 weeks of treatment.
At the start of the study, individuals with heroin addiction showed significantly impaired performance on the stop-signal task compared to healthy controls. This impairment was reflected in both their behavioral performance and reduced brain activity in key prefrontal regions, including the right anterior prefrontal cortex (aPFC) and the dorsolateral prefrontal cortex (dlPFC).
After 15 weeks of inpatient treatment, the iHUD group exhibited significant increases in brain activity in the aPFC and dlPFC during the stop-signal task. Importantly, these improvements in brain activity were associated with better performance on the stop-signal task, particularly in the ability to distinguish between targets and non-targets, indicating enhanced inhibitory control.
The study’s findings suggest that inpatient treatment can lead to measurable improvements in brain function related to self-control in individuals with heroin addiction. These results provide a hopeful perspective on the potential for recovery and underscore the importance of targeting cognitive control processes in addiction treatment.
“Using functional brain imaging, we examined inpatient individuals with heroin use disorder,” Ceceli told PsyPost. “We revealed that 15 weeks of medication-assisted treatment (including supplemental group therapy) improved impaired anterior and dorsolateral prefrontal cortex (PFC) function during an inhibitory control task. Inhibitory control, a core deficit in drug addiction, may be amenable to targeted PFC interventions.”
“While the clinical trial associated with the study is ongoing, we thought that the current results suggesting anterior and dorsolateral prefrontal cortex increases following a relatively short treatment were exciting and important enough to share in the interim. We are excited to identify these brain functions and regions as potential targets for modulation to help expedite and/or improve people’s ability to exert more control over their drug use, and more generally, their drug addiction treatment outcomes.”
The findings are promising, but the study — like all research — has some limitations. The sample size was relatively small, and the researchers could not definitively separate the effects of different treatment types. Long-term follow-up studies are necessary to determine whether these brain function improvements are sustained over time and translate into reduced relapse rates..
Future research will aim to replicate these findings in larger, more diverse samples. The researchers also plan to explore the specific contributions of different types of therapy to the observed improvements in brain function and behavior.
“Our results should be interpreted alongside consideration of its limitations,” Ceceli said. “More research is needed to determine whether a specific aspect of inpatient treatment, for instance medication-assistance, substantially contributes to improvement of PFC engagement during inhibitory control. This is a difficult question to address, as it may involve studying individuals who are abstaining from heroin without medication, potentially introducing confounds such as acute withdrawal.
“Next, larger samples than our study are needed to inspect individual differences (such as sex differences) in PFC activity. Last, our results do not provide evidence for measurably better self-control following treatment, as the individuals with substance use disorder were comparable in performance at the two time points.”
“The inpatient individuals in our study attended supplemental group therapy sessions for 8 of the 15 weeks they received medication-assisted inpatient treatment, randomized into mindfulness-based (Mindfulness Oriented Recovery Enhancement) and standard group therapy,” Ceceli added. “In future, we plan to test whether the recovery effects observed here are attributable to the mindfulness-based intervention.”
The study, “Recovery of anterior prefrontal cortex inhibitory control after 15 weeks of inpatient treatment in heroin use disorder,” was authored by Ahmet O. Ceceli, Yuefeng Huang, Pierre-Olivier Gaudreault, Natalie E. McClain, Sarah G. King, Greg Kronberg, Amelia Brackett, Gabriela N. Hoberman, John H. Gray, Eric L. Garland, Nelly Alia-Klein, and Rita Z. Goldstein.
